Aplastic Anemia: Diagnosing and Treating Bone Marrow Failure

Understanding Aplastic Anemia

Aplastic anemia is a rare but serious blood disorder characterized by the bone marrow's inability to produce sufficient new blood cells. This leads to a deficiency in all three types of blood cells: red blood cells (causing anemia), white blood cells (increasing infection risk), and platelets (leading to bleeding issues). This condition is a form of bone marrow failure [1].

Diagnosing Aplastic Anemia

The diagnostic process for aplastic anemia involves a thorough evaluation to distinguish it from other conditions that can cause similar symptoms, such as hypoplastic myelodysplastic syndromes [1]. Key indicators for aplastic anemia include a low count of all blood cell types (pancytopenia) and a bone marrow biopsy showing a reduced number of blood-forming cells (hypocellular bone marrow) [1].

Initial steps in diagnosing chronic anemia often involve a complete blood count (CBC) to identify abnormal cell counts [4]. Further specialized tests are then performed. The emerging use of molecular cyto-genomics, which examines genetic and chromosomal changes, is increasingly helpful in differentiating immune-mediated aplastic anemia from inherited bone marrow failure syndromes [1].

Assessing Disease Severity

Once aplastic anemia is diagnosed, its severity is assessed using specific criteria, such as the Camitta criteria [1]. This assessment is crucial because the severity of the disease, along with the patient's age and the availability of a human leukocyte antigen (HLA)-compatible donor, are key factors that determine the most appropriate treatment plan [1].

Treatment Approaches for Aplastic Anemia

Treatment for aplastic anemia aims to restore bone marrow function and manage the symptoms caused by low blood cell counts. The choice of treatment is highly individualized, taking into account the patient's age, the severity of their condition, and whether a suitable donor for a stem cell transplant is available [1].

First-Line Treatments for Severe Cases

For newly diagnosed patients with severe or very severe aplastic anemia, two primary first-line treatment options are considered [1]:

• Immunosuppressive Therapy (IST): This approach uses medications to suppress the immune system, which is believed to be attacking and damaging the bone marrow in many cases of acquired aplastic anemia. Standard IST typically involves horse anti-thymocyte globulin (ATG) and ciclosporin, often combined with eltrombopag [1].

• Allogeneic Hematopoietic Stem Cell Transplant (HSCT): This procedure involves replacing the patient's faulty bone marrow with healthy blood-forming stem cells from a matched donor. HSCT is a potentially curative option, especially for younger patients with a suitable donor [1].

Supportive Care

Supportive care is a critical component of aplastic anemia management throughout the entire disease course. It focuses on alleviating symptoms and preventing complications related to low blood cell counts [1].

• Blood and Platelet Transfusions: Patients often require transfusions of red blood cells to treat anemia and platelet transfusions to prevent or manage bleeding episodes [1].

• Infection Prevention and Management: Due to low white blood cell counts, individuals with aplastic anemia are highly susceptible to infections. Supportive care includes antimicrobial prophylaxis to prevent infections and prompt, aggressive management of any opportunistic infections that may arise [1].

Managing aplastic anemia requires a comprehensive and individualized approach, often involving a team of specialists to ensure the best possible outcomes for patients.

Sources

1. Guidelines for the diagnosis and management of adult aplastic anaemia: A British Society for Haematology Guideline.
2. Executive Summary of the KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease (CKD).
3. Plasma and Platelet Transfusion Strategies in Critically Ill Children Following Severe Trauma, Traumatic Brain Injury, and/or Intracranial Hemorrhage: From the Transfusion and Anemia EXpertise Initiative-Control/Avoidance of Bleeding.
4. How to approach chronic anemia.
5. Iron deficiency anemia--bridging the knowledge and practice gap.
6. Research Priorities for Plasma and Platelet Transfusion Strategies in Critically Ill Children: From the Transfusion and Anemia EXpertise Initiative-Control/Avoidance of Bleeding.
7. Updates in Neonatal Hematology: Causes, Risk Factors, and Management of Anemia and Thrombocytopenia.
8. A British Society for Haematology Guideline: Diagnosis and management of thrombotic thrombocytopenic purpura and thrombotic microangiopathies.